Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Key Highlights
- ➤Anteris will report first 30-day medium-size DurAVR THV outcomes at TCT 2026
- ➤Azeem Latib, MD, will present clinical and hemodynamic results November 1
- ➤Over 130 patients have received DurAVR THV across EMBARK and EFS since 2021
- ➤Santiago Garcia, MD, will showcase DurAVR technology in a November 3 TCT session
Expert Statements
Azeem Latib, MD; presenter of Anteris’ TCT 2026 clinical outcomes presentation
“The Novel Biomimetic Medium DurAVR THV Balloon-Expandable Valve (Anteris): First Report of the 30-Day Clinical and Hemodynamic Outcomes”
Santiago Garcia, MD; presenter of Anteris’ TCT 2026 emerging TAVR technologies session
“DurAVR TAVR (ANTERIS): Technology and Case-in-a-Box”
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR(®) Transcatheter Heart Valve (THV) at TCT(®) 2026 – The 38(th) Annual Transcatheter Cardiovascular Therapeutics Conference, taking place in San Diego, California, October 31-November 3, 2026.
The presentation will report 30-day outcomes in patients with severe aortic stenosis who received the medium-size DurAVR THV in the ongoing EMBARK study. Since 2021 over 130 patients have been treated with the DurAVR THV across different valve sizes in the Company’s EMBARK study and Early Feasibility Study (EFS).
Get started
Create a free account to read the full story.